Clinical data
Routes of
Subcutaneous injection
ATC code none
Legal status
Legal status
  • Investigational
Synonyms BA058, BIM-44058
CAS Number 247062-33-5
PubChem (CID) 76943386
ChemSpider 34443170
Chemical and physical data
Formula C174H299N56O49
Molar mass 3,959.65 g·mol−1
3D model (Jmol) Interactive image

Abaloparatide is a parathyroid hormone-related protein (PTHrP) analog drug in development for treating osteoporosis.[1] Like the related drug teriparatide, and unlike bisphosphonates, it is an anabolic (i.e., bone growing) agent.[2]

A subcutaneous injection formulation of the drug has completed a Phase III trial for osteoporosis.[3] This single study found a decrease in fractures.[4] A transdermal patch is also in development.[2]


  1. http://www.genengnews.com/gen-news-highlights/radius-raises-26-75m-for-phase-iii-osteoporosis-trial/81245990/
  2. 1 2 H. Spreitzer (18 January 2016). "Neue Wirkstoffe – Abaloparatid". Österreichische Apothekerzeitung (in German) (2/2016): 12.
  3. Clinical trial number NCT01343004 for "Phase III Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women" at ClinicalTrials.gov
  4. Miller, PD; Hattersley, G; Riis, BJ; Williams, GC; Lau, E; Russo, LA; Alexandersen, P; Zerbini, CA; Hu, MY; Harris, AG; Fitzpatrick, LA; Cosman, F; Christiansen, C; ACTIVE Study, Investigators. (16 August 2016). "Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.". JAMA. 316 (7): 722–33. PMID 27533157.

This article is issued from Wikipedia - version of the 10/26/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.